ORAMED PHARMACEUTICALS INC
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
| Three months ended | ||||
|---|---|---|---|---|
| March 31, | ||||
| 2025 · 2024 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net income (loss) | $(7,642) | $1,534 | ||
| Adjustments required to reconcile net income (loss) to net cash used in operating activities: | ||||
| Depreciation | 30 | 56 | ||
| Exchange differences and interest on deposits | 130 | (5) | ||
| Changes in fair value of investments | 3,348 | (3,748) | ||
| Stock-based compensation | 2,189 | 1,294 | ||
| Funded in respect of employee rights upon retirement | - | (2) | ||
| Change in accrued interest on short-term borrowings to maturity | - | 21 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | 667 | 36 | ||
| Accounts payable, accrued expenses and related parties | (185) | (666) | ||
| Net changes in operating lease | 1 | 3 | ||
| Deferred revenue | (2,000) | - | ||
| Liability for employee rights upon retirement | 3 | 1 | ||
| Other liabilities | (60) | - | ||
| Total net cash used in operating activities | (3,519) | (1,476) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchase of property and equipment | (3) | (2) | ||
| Purchase of short-term deposits | - | (4,000) | ||
| Proceeds from redemption of short-term deposits | 28,450 | 19,000 | ||
| Loan to investment in equity method | (7,000) | - | ||
| Equity method investee | (250) | - | ||
| Proceeds from loan to an equity method investee | 2,736 | - | ||
| Advance payments for real estate | (1,194) | - | ||
| Proceeds from investments | 877 | 15,000 | ||
| Total net cash provided by investing activities | 23,616 | 29,998 | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Loans repaid | - | (19,000) | ||
| Total net cash used in financing activities | - | (19,000) | ||
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | (1) | (1) | ||
| INCREASE IN CASH AND CASH EQUIVALENTS | 20,096 | 9,521 | ||
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 54,420 | 9,055 | ||
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $74,516 | $18,576 | ||
| (A) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS - | ||||
| Interest received | $1,183 | $1,341 | ||
| Interest paid | $ | - | $(571) | |
| (B) SUPPLEMENTARY DISCLOSURE OF NON-CASH ACTIVITIES | ||||
| Investment in equity method | $390 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.